Search in:

Advanced search

Cancer Management and Research Volume 11, 2019 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis

Shi-Tong Yu1 Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China, [email protected]

Jun-Na Ge1 Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China, [email protected]

Jing-Yi Luo2 State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China

Zhi-Gang Wei1 Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China, [email protected]

Bai-Hui Sun1 Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China, [email protected]

Shang-Tong Lei1 Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China, [email protected]Correspondence[email protected]

Pages 1525-1532 | Published online: 14 Feb 2019

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

References

SchneiderTCAbdulrahmanRMCorssmitEPMorreauHSmitJWKapiteijnELong-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trialEur J Endocrinol2012167564365022918300
PubMed Web of Science ®Google Scholar
BroseMSNuttingCMJarzabBSorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialLancet2014384994031932824768112
PubMed Web of Science ®Google Scholar
CabanillasMESchlumbergerMJarzabBA phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessmentCancer2015121162749275625913680
PubMed Web of Science ®Google Scholar
SchlumbergerMTaharaMWirthLJLenvatinib versus placebo in radioiodine-refractory thyroid cancerN Engl J Med2015372762163025671254
PubMed Web of Science ®Google Scholar
BerdelouABorgetIGodbertYLenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practiceThyroid Epub20171127
PubMed Web of Science ®Google Scholar
NervoAGalloMSamàMTLenvatinib in advanced radioiodine-refractory thyroid cancer: a snapshot of real-life clinical practiceAnticancer Res20183831643164929491097
PubMed Web of Science ®Google Scholar
BalmelliCRailicNSianoMLenvatinib in advanced radioiodine-refractory thyroid cancer - a retrospective analysis of the swiss lenvatinib named patient programJ Cancer20189225025529344270
PubMed Web of Science ®Google Scholar

References

CarlingTUdelsmanRThyroid cancerAnnu Rev Med20146512513724274180
PubMed Web of Science ®Google Scholar
GruberJJColevasADDifferentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patientsOncologist201520211312625616432
PubMed Web of Science ®Google Scholar
KapiteijnESchneiderTCMorreauHGelderblomHNortierJWSmitJWNew treatment modalities in advanced thyroid cancerAnn Oncol2012231101821471561
PubMed Web of Science ®Google Scholar
BroseMSNuttingCMJarzabBSorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialLancet2014384994031932824768112
PubMed Web of Science ®Google Scholar
CabanillasMEde SouzaJAGeyerSCabozantinib as salvage therapy for patients with tyrosine kinase Inhibitor-Refractory differentiated thyroid cancer: results of a multicenter phase II international thyroid Oncology Group trialJ Clin Oncol201735293315332128817373
PubMed Web of Science ®Google Scholar
Klein HesselinkENSteenvoordenDKapiteijnETherapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysisEur J Endocrinol20151725R215R22525572389
PubMed Web of Science ®Google Scholar
LeboulleuxSBastholtLKrauseTVandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialLancet Oncol201213989790522898678
PubMed Web of Science ®Google Scholar
SchlumbergerMTaharaMWirthLJLenvatinib versus placebo in radioiodine-refractory thyroid cancerN Engl J Med2015372762163025671254
PubMed Web of Science ®Google Scholar
SchneiderTCAbdulrahmanRMCorssmitEPMorreauHSmitJWKapiteijnELong-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trialEur J Endocrinol2012167564365022918300
PubMed Web of Science ®Google Scholar
BalmelliCRailicNSianoMLenvatinib in advanced radioiodine-refractory thyroid cancer - a retrospective analysis of the swiss lenvatinib named patient programJ Cancer20189225025529344270
PubMed Web of Science ®Google Scholar
NervoAGalloMSamàMTLenvatinib in advanced radioiodine-refractory thyroid cancer: a snapshot of real-life clinical practiceAnticancer Res20183831643164929491097
PubMed Web of Science ®Google Scholar
BerdelouABorgetIGodbertYLenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practiceThyroid Epub20171127
PubMed Web of Science ®Google Scholar
CabanillasMESchlumbergerMJarzabBA phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessmentCancer2015121162749275625913680
PubMed Web of Science ®Google Scholar
LocatiLDLicitraLAgateLTreatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessmentsCancer2014120172694270324844950
PubMed Web of Science ®Google Scholar
MarottaVdi SommaCRubinoMSecond-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenibEndocrine201549385485825305056
PubMed Web of Science ®Google Scholar
ResteghiniCCavalieriSGalbiatiDManagement of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patientsBest Pract Res Clin Endocrinol Metab201731334936128911730
PubMed Web of Science ®Google Scholar
ShermanSITargeted therapy of thyroid cancerBiochem Pharmacol201080559260120471374
PubMed Web of Science ®Google Scholar
LiuJWChenCLohEWTyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trialsCurr Med Res Opin201834579580328812918
PubMed Web of Science ®Google Scholar
GhataliaPJeYKaymakcalanMDSonpavdeGChoueiriTKQTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitorsBr J Cancer2015112229630525349964
PubMed Web of Science ®Google Scholar
KiyotaNSchlumbergerMMuroKSubgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancerCancer Sci2015106121714172126426092
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis

References

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis

References

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date